NeoGenomics Q2 2024 Adj. EPS $0.03 Beats $0.00 Estimate, Sales $164.502M Beat $161.847M Estimate
Portfolio Pulse from Benzinga Newsdesk
NeoGenomics (NASDAQ:NEO) reported Q2 2024 adjusted EPS of $0.03, beating the $0.00 estimate. Sales were $164.502M, surpassing the $161.847M estimate. This marks a significant improvement from the same period last year.
July 29, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeoGenomics reported Q2 2024 adjusted EPS of $0.03, beating the $0.00 estimate. Sales were $164.502M, surpassing the $161.847M estimate. This marks a significant improvement from the same period last year.
NeoGenomics' Q2 2024 earnings and sales both exceeded analyst estimates, showing significant improvement from the previous year. This positive financial performance is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100